Favorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function

• Published in: Therapeutic apheresis and dialysis 2022-02, Vol.26 (1), p.220-228
• Main Authors: Muso, Eri, Sakai, Soichi, Ogura, Youske, Yukawa, Susumu, Nishizawa, Yoshiki, Yorioka, Noriaki, Saito, Takao, Mune, Masatoshi, Sugiyama, Satoshi, Iino, Yasuhiko, Hirano, Tsutomu, Hattori, Motoshi, Watanabe, Tsuyoshi, Yokoyama, Hitoshi, Sato, Hiroshi, Uchida, Shunya, Wada, Takashi, Shoji, Tetsuo, Oda, Hiroaki, Mori, Kiyoshi, Kimura, Hideki, Ito, Osamu, Nishiyama, Akira, Maruyama, Shoichi, Inagi, Reiko, Fujimoto, Shoichi, Tsukamoto, Tatsuo, Suzuki, Yusuke, Honda, Hirokazu, Babazono, Tetsuya, Tsuruya, Kazuhiko, Yuzawa, Yukio
• Format: Article
• Language: English
• Subjects: Blood Component Removal - methods; Cohort Studies; eGFR; end‐stage renal disease; Humans; LDL apheresis; Lipoproteins, LDL - blood; nephrotic syndrome; Nephrotic Syndrome - blood; Nephrotic Syndrome - complications; Nephrotic Syndrome - therapy; Original; Prospective Studies; renal dysfunction; Renal Insufficiency - blood; Renal Insufficiency - complications; Renal Insufficiency - therapy; Treatment Outcome
• ISSN: 1744-9979; 1744-9987
• DOI: 10.1111/1744-9987.13694

Many reports have shown the therapeutic efficacy of LDL apheresis (LDL‐A) in drug‐resistant nephrotic syndrome (NS) for improvement of heavy proteinuria and severely impaired renal function. To obtain comprehensive results in a large number of cases, a post hoc analysis of the Prospective Observational survey on the Long‐Term Effects of the LDL‐Apheresis on the Drug Resistant Nephrotic Syndrome (POLARIS) study was performed by stratifying enrolled cases according to the pretreatment estimated glomerular filtration rate (eGFR) levels indicating normal (N) (≥60 ml/min/1.73 m2), moderately impaired (M) (≥30 to